- In April 2024, A study published in the European Respiratory Journal assessed the effectiveness of various OPEP devices, including the Acapella device, in facilitating mucus clearance in patients with chronic respiratory conditions. The findings support the clinical efficacy of OPEP therapy in improving pulmonary function and reducing exacerbations
- In April 2024, Trudell Medical International (TMI) conducted a study evaluating the medication delivery performance of hypertonic saline administered via a nebulizer with breath-actuated technology (inhalation) attached to an OPEP device (exhalation). This combination system demonstrated improved aerosol delivery efficiency, suggesting enhanced treatment outcomes for respiratory conditions
- In February 2024, a clinical study in Wales, UK, assessed the effectiveness of a handheld OPEP device in patients with Chronic Obstructive Pulmonary Disease (COPD) experiencing mucus hypersecretion after exacerbation. The study compared the OPEP device’s performance with the Active Cycle of Breathing Techniques (ACBT), providing important insights into clinical management of COPD symptoms
- In January 2024, Trudell Medical International published a laboratory investigation comparing four different OPEP devices, analyzing total pressure pulse impact (TPPI) and other performance metrics. The study aimed to guide clinicians in selecting the most effective OPEP device for respiratory therapy
- In January 2024, Trudell Medical International released a comprehensive study on the Aerobika Oscillating Positive Expiratory Pressure (OPEP) device, highlighting its effectiveness in improving lung function and quality of life for patients with chronic respiratory conditions. The study underscores the device's role in airway clearance therapy, offering a drug-free solution for managing diseases such as COPD and cystic fibrosis
